Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin. It was approved in April 2022 for the treatment of adults with symptomatic New York Heart Association (NYHA) class ...

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has updated the U.S.

Researchers from Rutgers Health and RWJBarnabas Health have developed an artificial intelligence (AI) technology that ...

Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients in the maintenance phase and expanded patient eligibility with reduced contraindication ...

Whereas obesity is a common confounder when interpreting natriuretic peptide values, and the presence of atrial fibrillation has an important influence on pretest probability, other confounders are ...

Preventing onset and development of heart failure with preserved ejection fraction Date: April 15, 2025 Source: Baylor College of Medicine Summary: An international team of researchers has ...